Metastatic and Advanced SFT

What Does Metastatic or Advanced SFT Mean?

You may hear your doctors use several terms to describe your disease.

SFT can spread to areas such as the lungs, liver, bones, and other tissues.

Some people have only one or two areas of disease. Others have several tumors in different locations.

The location, number, size, and growth rate of the tumors all matter when making treatment decisions.

Having metastatic SFT does not automatically mean you need to begin medication immediately. For some patients, local treatment or careful monitoring may be appropriate.

How Is Treatment Planned?

There is no single treatment plan that works for everyone with advanced SFT.

Your doctors will consider several things:

A multidisciplinary sarcoma team can help evaluate these factors and recommend options.

Depending on your situation, treatment may aim to:

• Remove or destroy tumors that can be safely treated.
• Shrink tumors or slow their growth.
• Prevent or relieve symptoms.
• Protect important organs and normal function.
• Maintain or improve quality of life.
• Provide long-term disease control.

Some people may have more than one of these goals.

Ask your doctors to explain what they hope a treatment will accomplish and how they will measure success.

Do I Need Treatment Right Away?

This is one of the most important questions to discuss with your care team.

Some SFTs grow slowly, even after spreading. If the disease is not causing symptoms or threatening important organs, your doctor may recommend continued monitoring before beginning treatment.

This approach is called active surveillance.

It involves regular imaging and clinical visits to watch for changes.

Other situations require more immediate treatment, particularly when tumors are growing quickly, causing symptoms, or affecting organ function.

If monitoring is recommended, ask

• Why is it reasonable to monitor my disease right now?
• How often will I have scans?
• What changes would prompt treatment?
• Are there risks to delaying treatment?

Active surveillance is a planned medical approach and requires appropriate follow-up.

Local Treatments for Advanced SFT

Even when SFT has spread, treatments directed at individual tumors may still be useful.

These are sometimes called local therapies.

Surgery may be considered when one or a small number of tumors can be safely removed.

For some patients, removing metastatic tumors may provide meaningful periods of disease control.

The decision depends on the location and number of tumors, how the disease is behaving elsewhere, and the risks of surgery.

Radiation may be used to treat tumors that cannot be removed or are causing symptoms.

Highly focused techniques, such as stereotactic body radiation therapy (SBRT) or stereotactic radiosurgery (SRS), may be appropriate for selected tumors.

Radiation may help control local disease while limiting exposure to nearby tissues.

Ablation destroys tumor tissue using heat, cold, or other energy, often through a needle guided by imaging.

It may be useful for selected tumors in the lungs, liver, or other locations.

Sometimes most tumors remain stable while one or two begin growing. Doctors call this oligoprogression.

In selected cases, those growing spots may be treated with surgery, radiation, or ablation while other treatment continues.

Ask your specialist whether local treatment could be useful, even if you have disease in more than one location.

Medicines Used to Treat Advanced SFT

When SFT cannot be controlled adequately with local treatments, doctors may recommend medicines that work throughout the body. This is called systemic therapy.

There is no universally accepted medication sequence for advanced SFT, and not everyone responds to the same treatment.

Some medicines have shown activity in clinical studies of SFT, while others have been used based on experience treating sarcoma.

SFTs often have an extensive network of blood vessels.

Some medicines interfere with the signals involved in blood vessel growth. These are called antiangiogenic therapies.

Examples include:

• Pazopanib (Votrient)
• Axitinib (Inlyta)
• Sunitinib (Sutent)

Pazopanib has some of the strongest clinical evidence among medicines studied specifically for advanced non-dedifferentiated SFT.

These medicines may slow tumor growth, stabilize disease, or shrink tumors in some patients.

Possible side effects include high blood pressure, fatigue, diarrhea, and changes in liver function. Specific risks and monitoring differ between medicines.

Your oncologist will explain which treatment may be appropriate and how your health will be monitored.

Another approach combines two medicines:

• Temozolomide: An oral chemotherapy that damages tumor cell DNA.
• Bevacizumab (Avastin): An intravenous medicine that blocks a signal involved in blood vessel growth.

This combination has shown activity in some patients with advanced SFT.

Possible side effects include fatigue, low blood counts, high blood pressure, bleeding, and other complications.

Your care team will consider your medical history and treatment goals when deciding whether this combination is appropriate.

Traditional chemotherapy may be considered, particularly for tumors that are growing rapidly or have a more aggressive appearance.

Medicines used in selected circumstances include:

• Doxorubicin
• Dacarbazine
• Trabectedin

Their effectiveness varies, and the evidence for SFT is more limited than for some other cancers.

Chemotherapy can cause side effects such as nausea, fatigue, and low blood counts. Some drugs have additional risks, such as effects on the heart.

A small proportion of SFTs develop a more aggressive form called dedifferentiated SFT.

These tumors may behave differently and respond differently to treatment.

Chemotherapy is often considered more prominently for dedifferentiated SFT, although the best approach remains uncertain.

If your pathology report mentions dedifferentiation, ask your oncologist to explain how it affects your treatment options.

How Will We Know Whether Treatment Is Working?

This is an important part of living with advanced SFT.

Your doctor will usually use scans, symptoms, physical examinations, and other findings to evaluate treatment.

A treatment can be useful even if tumors do not become dramatically smaller.

Doctors may look for:

Your doctor may use different methods to evaluate scans, depending on the treatment and circumstances.

Ask how soon your next scan will occur and what results would indicate that treatment is helping.

Tell your care team about symptoms that affect your daily life.

Depending on the medicine and situation, your doctor may be able to adjust the dose, temporarily interrupt treatment, recommend supportive medicines, or consider another option.

Do not change or stop a prescribed cancer medicine without discussing it with your treatment team.

What Happens if Treatment Stops Working?

Advanced SFT may change over time.

A medicine that once controlled the disease may become less effective. Sometimes only a few tumors begin growing while others remain stable.

If that happens, your team may consider:

• Continuing treatment with closer monitoring, in selected circumstances
• Treating a small number of growing tumors locally
• Adjusting or changing medicines
• Reviewing the pathology or considering additional molecular testing
• Exploring a clinical trial
• Reassessing your goals and treatment priorities

Progression does not always mean every treatment option has been exhausted.

Ask your oncologist what alternatives may be available and whether another specialist’s opinion would help.

Clinical Trials and New Treatments

Because SFT is rare, research is essential to improving treatment options.

Clinical trials help researchers evaluate new medicines, treatment combinations, and other approaches.

Some trials are specifically designed for SFT. Others accept people with several types of soft tissue sarcoma or certain molecular characteristics.

It’s worth discussing clinical trials early, including before beginning a new systemic treatment.

Areas of investigation include:

New targeted therapies

Medicines designed to interfere with biological pathways involved in SFT growth.

Combination treatments

Approaches that combine antiangiogenic medicines with other therapies.

Immunotherapy

Treatments intended to help the immune system recognize or attack cancer cells.

Radioligand therapies

Experimental treatments that use a targeting molecule to deliver radiation to certain tumor-associated cells.

Molecularly guided treatments

Therapies selected using specific biological characteristics of a tumor.

Some approaches have shown promising results in laboratory studies or individual patients. More research is needed to establish their safety and effectiveness in SFT.

You can explore studies through:

• ClinicalTrials.gov: Solitary Fibrous Tumor
• ClinicalTrials.gov: Soft Tissue Sarcoma
• National Cancer Institute Clinical Trials Search
• SARC Clinical Trials

A trial may be relevant even if SFT is not mentioned in its title.

Ask your oncologist or a sarcoma center to review eligibility requirements, including previous treatments, health conditions, and any required molecular tests.

Also ask about travel, lodging, insurance, and other costs before deciding whether a trial is practical.

For more information, see Part 9: Joining Research.

Managing Symptoms and Quality of Life

Living with advanced SFT can involve more than managing tumor growth.

You may experience symptoms from the disease, side effects from treatment, emotional stress, or changes in your ability to work and participate in daily activities.

Tell your care team what you’re experiencing, including problems that may seem unrelated to cancer treatment.

Palliative care focuses on relieving symptoms, reducing suffering, and improving quality of life for people with serious illnesses.

It can help with:

• Pain and discomfort
• Fatigue and sleep problems
• Nausea and appetite changes
• Emotional stress and anxiety
• Communication and difficult treatment decisions
• Support for caregivers and families

Palliative care can be provided alongside active cancer treatment, including surgery, radiation, and medicines.

You can ask for this support at any point. You do not need to wait until treatment options are limited.

Treatment decisions may affect your energy, mobility, travel, work, family responsibilities, and other activities.

Let your care team know which parts of your life matter most.

You might want to remain physically active, preserve independence, avoid certain side effects, continue working, or spend less time traveling for treatment.

These priorities can help shape your care plan.

For more information, see Part 7: Living with SFT.

Staying Organized as Your Care Changes

Advanced SFT often involves multiple treatments, specialists, and follow-up appointments.

Keeping a clear treatment history can help your care team make decisions.

For each treatment, try to record

• Medicine or procedure name
• Start and end dates
• Dose or treatment details, when available
• How the tumors responded
• Side effects or complications
• Why the treatment was changed or stopped

Keep your previous scan images, pathology reports, and other important records accessible.

If you receive care from several medical centers, ask who is responsible for coordinating treatment decisions.

See Preparing for a Visit.

Your Next Steps

Use this checklist to help prepare for conversations about advanced SFT.

• Understand your disease. Ask where tumors are located, how they are changing, and whether they are causing problems.
• Review your options. Discuss monitoring, local treatments, systemic medicines, and clinical trials.
• Get specialist input. Ask whether your case has been reviewed by an experienced sarcoma team.
• Clarify your treatment goals. Understand what each treatment is intended to accomplish.
• Plan for monitoring. Know when your next scan will be and how results will be assessed.
• Discuss side effects and support. Ask how symptoms and treatment-related problems can be managed.
• Plan ahead. Understand what options may be available if your disease changes.